Charles Crocker is a principal of Crocker Capital, a private venture capital firm active in
life sciences. He recently served as Chairman of the Board and CEO of BEI Technologies, Inc., a public, diversified
technology company that he founded and was recently sold to Schneider Electric. He was Chairman, CEO, and founder of
BEI Medical Systems, a public medical device company that was sold to Boston Scientific. He serves on the boards of
Franklin Resources, Inc. and its subsidiaries (parent of the Franklin Templeton Funds), Mercator MedSystems, Inc.,
Pope & Talbot, Inc. and Teledyne Technologies, Inc. He is Chair of the Franklin Compensation Committee and Chair
of the Pope and Talbot Audit Committee. Mr. Crocker has been Chairman of the Board of Children's Hospital in
San Francisco, Chairman of the Hamlin School's Board of Trustees, President of the Foundation of the Fine
Arts Museums of San Francisco, and a Trustee of the Buck Center for Research in Aging. He currently serves
as a Trustee of the Mary A. Crocker Trust. Mr. Crocker received his B.S. degree from Stanford University and
an M.B.A from the University of California, Berkeley.
John Maki
Director
John Maki is President and CEO of Vicus Therapeutics, LLC.
Mr. Maki was previously Managing Director of Technology Directors Inc., an early-stage life science venture
capital firm, Managing Director of Audax Group, a multi-asset class private equity firm, Principal of Bain
Capital, a private alternative asset management company and a Consultant of Bain & Company, a business
consulting firm. Mr. Maki currently serves on the boards of 3DMatrix, a bone regeneration device company
and Addition Technology, an ophthalmic device company and has been founding investor and/or board member
of eleven life science companies. Mr. Maki also serves on the Board of Trustees of BIO NJ. Mr. Maki received
his A.B. degree from Harvard University.
Arch Meredith,
Director
Arch Meredith is Managing Partner of Kite Hill Capital, a private venture capital
firm. He is also Co-Founder of the Chroma Group and manages Chroma Group equity interests in
Chroma Exploration & Production, Quantitative Imaging, and Vicus Therapeutics. Previously he
was founder and CEO of TeleTix (acquired by Transamerica) and a principal at Salomon Brothers
and McKinsey & Company. He serves on the boards of Chroma Group and Quantitative Imaging. Mr.
Meredith received his B.A. degree from Stanford University and an M.B.A. from the Stanford
Graduate School of Business.
